Lab. ofThermo-therapeutics for vascular dysfunction

The University of Osaka Graduate School of Medicine

Publications

  1. Shima Y, Uchida-Yamada M, Motegi S, Shimada T, ishii H, Ohya Y, Kanai Y. Factors Influencing Treatment Satisfaction and Recognition Gaps Between Physicians and Patients with Systemic Sclerosis. Rheumatol Ther. 2025; 12: 297-314.
  2. Shima Y, Watanabe A, Inoue N, Maruyama T, Kunitomo E, Matsushima Y, Kumanogoh A. Increased angiopoietin-1 improves nailfold capillary morphology in patients with systemic sclerosis. Microvasc Res. 2025; 157: 104761.
  3. Kuwana M, Takehara K, Tanaka Y, Yamashita K, Katsumata K, Takata M, Shima Y. Efficacy and safety of tocilizumab in Japanese patients with systemic sclerosis and associated interstitial lung disease: A subgroup analysis of a global, randomised, controlled Phase 3 trial. Mod Rheumatol. 2024; 34: 530-540.
  4. Ishikawa Y, Tanaka N, Asano Y, Kodera M, Shirai Y, Akahoshi M, Hasegawa M, Matsushita T, Saito K, Motegi SI, Yoshifuji H, Yoshizaki A, Kohmoto T, Takagi K, Oka A, Kanda M, Tanaka Y, Ito Y, Nakano K, Kasamatsu H, Utsunomiya A, Sekiguchi A, Niiro H, Jinnin M, Makino K, Makino T, Ihn H, Yamamoto M, Suzuki C, Takahashi H, Nishida E, Morita A, Yamamoto T, Fujimoto M, Kondo Y, Goto D, Sumida T, Ayuzawa N, Yanagida H, Horita T, Atsumi T, Endo H, Shima Y, Kumanogoh A, Hirata J, Otomo N, Suetsugu H, Koike Y, Tomizuka K, Yoshino S, Liu X, Ito S, Hikino K, Suzuki A, Momozawa Y, Ikegawa S, Tanaka Y, Ishikawa O, Takehara K, Torii T, Sato S, Okada Y, Mimori T, Matsuda F, Matsuda K, Amariuta T, Imoto I, Matsuo K, Kuwana M, Kawaguchi Y, Ohmura K, Terao C. GWAS for systemic sclerosis identifies six novel susceptibility loci including one in the Fcγ receptor region. Nat Commun. 2024; 15: 319.
  5. Shima Y, Watanabe A, Inoue N, Maruyama T, Kunitomo E, Kumanogoh A. Heating of the neck or elbows alleviates Raynaud's phenomenon but has different effects on different types of patients with systemic sclerosis. Mod Rheumatol. 2023; 34: 750-755.
  6. Konaka H, Kato Y, Hirano T, Tsujimoto K, Park J, Koba T, Aoki W, Matsuzaki Y, Taki M, Koyama S, Itotagawa E, Jo T, Hirayama T, Kawai T, Ishii KJ, Ueda M, Yamaguchi S, Akira S, Morita T, Maeda Y, Nishide M, Nishida S, Shima Y, Narazaki M, Takamatsu H, Kumanogoh A. Secretion of mitochondrial DNA via exosomes promotes inflammation in Behçet's syndrome. EMBO J. 2023; 42: e112573.
  7. Makimoto K, Shiozawa K, Shima Y, Hirano T, Inoue M, Understanding Patients' Symptoms Management Using Objective and Subjective Indicators among Patients with Systemic Lupus Erythematosus. Open Journal of Nursing 2023; 13: 314-328
  8. Inoue M, Shiozawa K, Yoshihara R, Shima Y, Hirano T, Makimoto K. Monitoring of Sleep Indicators, Physical Activity, Pain, and Fatigue in Patients with Systemic Lupus Erythematosus and Relations among These Variables: A Pilot Study. Open Journal of Nursing 2023; 13: 22-44
  9. Yoshida F, Kato T, Shima Y, Hatano K, Kawashima A, Fukuhara S, Imamura R, Nonomura N. Drug-induced interstitial pneumonia after intravesical Bacillus Calmette-Guerin administration for bladder cancer with scleroderma. IJU Case Rep. 2023; 6: 133-136.
  10. Watanabe A, Shima Y, Takahashi H, Akiyama Y, Kodera M, Jinnin M, Azuma N, Ishii K, Kumanogoh A. Arm heating to relieve Raynaud's phenomenon in systemic sclerosis: A single-arm multicentre prospective clinical trial. Mod Rheumatol. 2023; 33: 968-974
  11. Shima Y, Watanabe A, Inoue N, Maruyama T, Kunitomo E, Hamano K, Kawanishi T, Takasugi M, Kumanogoh A. Proximal heat stress up-regulates angiopoietin-1 in fingers and reduces the severity of Raynaud's phenomenon in systemic sclerosis: a single-centre pilot study. Mod Rheumatol. 2022; 32: 351-357.
  12. Shima Y. Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy. Cells 2021;10:1104.
  13. Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, Allanore Y, Matucci-Cerinic M, Distler O, Shima Y, van Laar JM, Spotswood H, Wagner B, Siegel J, Jahreis A, Denton CP; focuSSced investigators. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020; 8: 963-974.
  14. Shima Y, Watanabe A, Inoue N, Kunitomo E, Maruyama T, Site-specific study of hearing in healthy participants. The Journal of Japanese Society of Balneology, Climatology and Physical Medicine 2020; 83:105-112.
  15. Tanaka S, Ise W, Inoue T, Ito A, Ono C, Shima Y, Sakakibara S, Nakayama M, Fujii K, Miura I, Sharif J, Koseki H, Koni PA, Raman I, Li QZ, Kubo M, Fujiki K, Nakato R, Shirahige K, Araki H, Miura F, Ito T, Kawakami E, Baba Y, Kurosaki T. Tet2 and Tet3 in B cells are required to repress CD86 and prevent autoimmunity. Nature Immunol. 2020; 21: 950-961.
  16. Shima Y. The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis. The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis. Mod Rheumatol. 2019; 29: 294-301.
  17. shima Y, Akimoto T, Ike K, Nishino S, Kobayashi Y, Fujiwara Y. A case of rheumatoid arthritis who became able to use ready-made prefilled auto-injectors because of the development of self-assistive devices. Clin Rheumatol Rel Res. 2019;31:204-210.
  18. Shima Y, Kawaguchi Y, Kuwana M. Add-on tocilizumab versus conventional treatment for systemic sclerosis, and cytokine analysis to identify an endotype to tocilizumab therapy. Mod Rheumatol. 2019; 29: 134-139.
  19. Inoue M, Shiozawa K, Yoshihara R, Yamane T, Shima Y, Hirano T, Makimoto K. Predictors of poor sleep quality in patients with systemic lupus erythematosus. Clin Rheumatol. 2017; 36: 1053-1062.
  20. Morita T, Fujimoto K, Shima Y, Ogata A, Kumanogoh A. Minimal neonatal transfer of certolizumab pegol in a Japanese patient with rheumatoid arthritis. Ann Rheum Dis. 2018; 77: e56.
PAGE TOP